TrialRheumatology (Oxford, England)2019

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Jürgen Braun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.